Apeloa Pharmaceutical Co (000739) Fair Value & Analysis

Healthcare · CN · Market cap 18.9B CNY

A solid business, but screening 37% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case (¥18.08). The favourable scenario is already priced in.
• Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.

How to read this chart

60‑month range ¥10.19 – ¥37.24 · fair‑value band ¥11.64 – ¥18.08 · the ¥23.41 price screens above the ¥14.86 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 21, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Apeloa Pharmaceutical Co (000739) currently trades at ¥23.41, while our model-based Fair Value estimate is ¥14.86, implying the stock looks roughly 36.5% overvalued today. The Quality Score stands at 67/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Apeloa Pharmaceutical Co generated revenue of 9.5B CNY at a net margin of 9.4%. Revenue declined 10.4% year over year. It earns a return on equity of 13.1%. The balance sheet holds a net cash position of 2.3B CNY. Fundamentals as of Jul 21, 2026

Our scenario range runs from ¥11.64 (bear case) to ¥18.08 (bull case); at ¥23.41, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 78% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at -37%, 000739 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (¥22.07) versus Asset-Based (¥3.67). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Apeloa Pharmaceutical Co.,Ltd provides raw materials various pharmaceutical factories in the People's Republic of China and internationally. The company operates through API, CDMO, and Pharmaceutical segments.

Full company description

Apeloa Pharmaceutical Co.,Ltd provides raw materials various pharmaceutical factories in the People's Republic of China and internationally. The company operates through API, CDMO, and Pharmaceutical segments. It offers API intermediates business, which includes cephalosporin, penicillin, psychotropic, cardiovascular and cerebrovascular, and veterinary API intermediates series; innovative drug R&D and production services CDMO include R&D services, commercial human drug projects, commercial veterinary drug projects and other commercial projects; pharmaceutical business includes anti-infective, cardiovascular, psychotropic, hepatobiliary and anti-tumor categories. The company also provides technology platforms, such as flow chemistry, synthetic biology and biocatalysis, crystallization and particle engineering, peptide, high potency compound, conjugate library service, oligonucleotide synthesis, and preparation and purification; and controlled-release formulation development, taste masking technology, and particle flow simulation. In addition, it exports its products under the Tianliwei, Baishixin, Li'an, Jutai, and other brands. Apeloa Pharmaceutical Co.,Ltd was founded in 1989 and is based in Dongyang, the People's Republic of China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Apeloa Pharmaceutical Co reported revenue of ¥9.8B in FY2025 versus ¥8.9B in FY2021, a compound +2.2%/yr. Reported net income was ¥891M in FY2025, compounding −1.7%/yr from FY2021.

000739 screens 37% overvalued. Compare with Jiangsu Hengrui Pharmaceuticals Co →

Peer Group

Drug Manufacturers - Specialty & Generic · 626 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.